JWH-197

JWH-197 is a synthetic cannabinoid that was developed by Dr. John W. Huffman in the 1990s. It is part of a series of compounds that were created to study the structure-activity relationships of cannabinoids. JWH-197 is known for its high affinity for the CB1 receptor, which is primarily found in the central nervous system, and the CB2 receptor, which is primarily found in the peripheral tissues.

Chemical Structure and Properties

JWH-197 belongs to the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthyl group attached to a methylindole moiety. The compound has a molecular formula of C24H26O2 and a molecular weight of 346.47 g/mol.

Pharmacology

JWH-197 acts as a potent agonist at both the CB1 and CB2 receptors. The activation of these receptors by JWH-197 leads to a variety of physiological effects, including alterations in mood, perception, and cognition. The compound's high affinity for the CB1 receptor is responsible for its psychoactive effects, which are similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Legal Status

The legal status of JWH-197 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of accepted medical use. In the United States, JWH-197 and other synthetic cannabinoids are listed as Schedule I substances under the Controlled Substances Act.

Research and Applications

JWH-197 has been used in scientific research to better understand the endocannabinoid system and the role of cannabinoid receptors in the body. Studies involving JWH-197 have contributed to the development of new therapeutic agents targeting the cannabinoid system for the treatment of various conditions, including pain, inflammation, and neurological disorders.

Safety and Toxicity

The safety profile of JWH-197 is not well-established, as it has not been extensively studied in humans. However, synthetic cannabinoids, in general, have been associated with a range of adverse effects, including anxiety, paranoia, tachycardia, and in severe cases, psychosis and seizures. The use of JWH-197 outside of a controlled research setting is not recommended due to these potential risks.

Also see

• Synthetic cannabinoids
• John W. Huffman
• CB1 receptor
• CB2 receptor
• Tetrahydrocannabinol
• Cannabis